A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and efficacy of repeated
subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
A Bone Substudy will evaluate the effects of single-blind KRN23 versus Placebo on bone
mineral density and bone quality.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Pharma, Inc.
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.